Redeye comments on Lipigon's licensing agreement with Leaderna for Greater China.
Q2e: sales SEK 245m, EBITA 6.8%, EPS SEK 0.57 Expect order book realisation to continue, outlook pro...
Taaleri announced after market close that it has exited Forest Fund III with IRR of around 10%.
Redeye comments on Smart Eye's breakthrough deal for AIS with Linde.
Samtrygg genomför nu en företrädesemission med teckningsperiod 21 juni - 7 juli.
Ecoclime uppvisade stark tillväxt i Q1 om 38% men resultatet var fortsatt svagt.
Redeye endorses Qlife’s new strategy, which will allow life science companies to use Qlife’s platfor...
Marknaden är oförändrad sedan Q1-annonseringen – anpassar kostnadskostymen För att hantera de uppskj...
Analysguiden uppdaterar investeringscaset i Coor. En marknadsledare med stabil historik vars aktie e...
Redeye briefly comments on NeoDynamics’ rights issue.
Redeye is encouraged to see that OXE Marine has received another order from the US Defense Logistics...
Redeye retains its positive view of Transtema despite lowering our forecasts and Base Case.
Över 64 miljoner patienter lider av hjärtsvikt världen över och varje år uppgår dödssiffran till omk...
Redeye takes a positive view regarding the entrance of Alta Fox, a respected US-based investment fir...
Redeye updates its view on Beyond Frames following its recent successful game releases (through its ...
DT has successfully navigated through external obstacles and now has a prime opportunity to concentr...
AAC Clyde Space has announced a rights issue to raise SEK73.
Redeye initiates coverage of Pagero, a software-as-a-service (SaaS) company that helps businesses si...
Redeye view yesterdays announcement of a cost cutting program as a sign that the market is developin...
Redeye comments on Scandinavian ChemoTech’s latest supplier contract with MedVet Group and the initi...
